Recursion Pharmaceuticals RXRX Cash Flow Statement (2020-2026)

NASDAQ RXRX
$3.62 +0.17 (+5.09%)
As of: Sep 4, 2026 · 12:49 PM EDT
Reported Financials

Recursion Pharmaceuticals Quarterly Cash Flow Statement

Periods 26 quarters
Latest Jun 2026

Recursion Pharmaceuticals reported cash from operations of -$105.95M and free cash flow of -$105.99M for the quarter ended Jun 2026, down 38.6% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-46.40M-64.96M-55.98M-66.19M-62.57M-60.98M-65.33M-76.73M-93.02M-93.00M-91.37M-97.54M-95.84M-178.91M-202.49M-171.90M-162.25M-108.12M-117.50M-131.00M
Share-based CompensationStock Comp.
3.36M4.34M7.55M3.76M8.91M7.70M8.81M89.98M-7.77M-1.76M16.13M16.52M18.25M579.22M36.06M26.16M25.24M23.76M22.21M19.50M
Deferred Taxes
-0.42M0.64M-4.60M-0.00M
Asset Writedowns and ImpairmentWritedown
2.81M1.17M0.02M0.11M5.96M
Cash from OperationsCash from Ops.
-33.05M-61.16M77.39M-61.62M-54.54M-44.75M-73.32M-67.47M-72.92M-74.08M-102.30M-82.22M-59.23M-115.43M-131.96M-76.42M-117.36M-46.07M-81.10M-105.95M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
2.44M2.24M2.77M2.79M2.99M3.21M3.73M5.54M7.58M7.55M7.38M8.97M7.20M12.95M19.33M23.85M21.04M19.48M19.67M18.17M
Change in Working Capital
Change in ReceivablesChange Receivables
-0.02M
Change in Account PayablesChange Payables
3.13M-3.51M1.34M-0.99M0.71M0.69M-0.34M-2.52M2.19M-0.32M1.17M-1.34M-1.51M8.12M3.69M-4.84M-5.89M4.42M2.07M-7.67M
Change in Accured ExpensesChange Accured Exp.
10.13M1.64M-15.90M1.07M2.09M12.16M-9.85M6.20M7.58M2.78M-18.86M7.51M6.35M10.52M-26.59M11.38M-8.03M15.84M-18.45M5.83M
Other Working Capital ChangesOther WC Changes
-2.50M-2.50M144.70M-7.65M-13.05M-13.68M-12.13M-11.07M-10.16M-7.72M-13.65M-12.64M3.92M-5.66M-9.76M-13.62M-6.63M-6.76M-2.25M-7.30M
Investing Activities
Capital ExpendituresCapex
9.71M4.46M4.34M16.48M8.26M7.98M5.17M3.97M0.74M2.07M6.65M1.18M4.56M1.30M1.83M3.15M0.24M1.24M0.26M0.04M
Acquisitions
0.07M-277.10M
Divestments
-4.44M
Change in Acquisitions & DivestmentsChange Acquisitions
69.19M147.65M21.41M61.55M0.48M
Cash from Investing ActivitiesCash from Investing
-193.87M-52.24M143.30M4.94M52.98M-7.98M-5.34M-2.05M-0.35M-2.49M-6.65M-4.18M-4.56M275.46M-7.27M-5.81M-2.55M-1.24M-0.34M-1.96M
Financing Activities
Other financing activitiesOther financing
-454.46M2.11M2.69M2.36M3.57M1.95M3.81M3.79M3.26M3.05M1.60M1.78M1.71M1.55M2.74M-0.99M0.79M
Cash from Financing ActivitiesCash from Financing
-11.10M3.80M2.08M2.67M2.34M147.26M1.92M3.79M53.77M80.66M13.90M263.12M16.46M10.64M40.53M97.66M251.34M132.01M-3.47M-1.27M
Change in Capital Stock
Net Equity Issued and RepurchasedNet Equity Issued
462.90M50.00M78.09M10.87M261.55M16.97M11.03M41.02M100.00M254.46M133.38M
Additional items
Exchange Rate EffectFX Effect
-0.31M-0.00M0.18M-0.12M0.12M-0.22M-0.12M0.40M-3.47M4.83M9.26M1.87M2.09M-3.83M0.81M
Change in Cash
-238.02M-109.61M222.78M-54.02M0.78M94.22M-76.73M-65.55M-19.62M4.22M-95.28M176.60M-46.92M167.19M-93.87M24.69M133.30M86.78M-88.74M-108.36M
Free Cash FlowFCF
-42.75M-65.62M73.05M-78.10M-62.80M-52.73M-78.49M-71.44M-73.67M-76.14M-108.95M-83.40M-63.79M-116.73M-133.79M-79.57M-117.60M-47.32M-81.36M-105.99M
Net Cash FlowNCF
-238.02M-109.61M222.78M-54.02M0.78M94.53M-76.73M-65.73M-19.50M4.09M-95.06M176.72M-47.33M170.66M-98.70M15.43M131.43M84.69M-84.91M-109.17M